Healthcare Global Enterprises Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹10.7K Cr
Revenue growth outlook for FY '25 and beyond remains strong, with Q3 FY '25 recording a 19% year-on-year increase. Expectation of strong year-on-year growth in both top line and bottom line for the next financial year (FY26), as stated by Raj Gore.
From Healthcare Global Enterprises Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹726
Market Cap
₹10.7K Cr
P/E Ratio
221.3
How does Healthcare Global Enterprises Ltd rank in Healthcare Services?
Compare Healthcare Global Enterprises Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Healthcare Global Enterprises Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹652 Cr, net profit ₹4 Cr.
Full financials →📊 Revenue & Sales Performance
- →Revenue growth outlook for FY '25 and beyond remains strong, with Q3 FY '25 recording a 19% year-on-year increase.
- →Established centers are expected to grow at 13-14% going forward, outpacing the market growth rate of around 11%.
- →Emerging centers show exceptional performance, with 25% revenue growth in Q3 and expected continued strong growth.
- →New centers in Bangalore (brownfield expansions) will initially generate operating losses but are expected to be operationalized by FY '26.
- →The company plans to focus on organic plus brownfield growth primarily, with potential inorganic growth (mergers/acquisitions) to be considered in due course.
- →International patient revenue contribution expected to maintain at 3.5-4% with hopes of recovery in South Mumbai center as geopolitical issues ease.
- →Overall growth is expected to continue on both top line and bottom line next year, aiming for year-on-year improvements.
📈 Profitability & Margins
- →Expectation of strong year-on-year growth in both top line and bottom line for the next financial year (FY26), as stated by Raj Gore.
- →EBITDA margin expected to expand by approximately 1% to 1.5% in FY26 compared to FY25, despite operating losses from new centers.
- →Established centers projected to grow revenue at 13-14%, outpacing market growth (~11%).
- →Emerging centers showing rapid growth, contributing to margin expansion and reduced losses, e.g., South Mumbai center expected to break even by Q1 FY26.
- →Overall PAT grew 23% YoY in Q3 FY25; continued revenue and EBITDA growth momentum anticipated for Q4 FY25 and beyond.
- →Strong operational and clinical excellence focus to drive sustained profitability improvements.
- →Debt levels comfortable, supporting capex and growth without pressure on financials.
🏗️ Capital Expenditure Plans
- →Current and near-term capex guidance is INR 275–280 crores per annum for FY '25 and FY '26.
- →Of this, approximately INR 100 crores annually is maintenance capex.
- →Growth capex related to new centers and expansions is expected to be largely completed by FY '26.
- →Post FY '26, capex will normalize to around INR 100 crores per annum (maintenance), with some inflation.
- →Strategic investments include operationalizing two new brownfield centers in Bangalore in FY '26.
- →Focus on hub-and-spoke model infusion clinics and new centers in Bangalore for growth.
- →Potential mergers and acquisitions, particularly strategic oncology centers, to augment growth alongside organic and brownfield expansions.
- →Emphasis on research, academics, and precision medicine with new partners (KKR) to drive long-term growth.
💰 Fundraising & Capital Structure
- →No explicit mention of new fundraising through debt or equity in the call.
- →Current debt is about INR1,500 crores including capital leases; net debt excluding capital leases is about INR650 crores.
- →Company is comfortable with current debt levels given ongoing growth and capex plans.
- →Capex for FY '25 and FY '26 is planned around INR275-280 crores annually, mostly funded within existing resources.
- →Focus remains on organic and brownfield expansion with potential strategic mergers/acquisitions, to be discussed with new partner KKR.
- →Any inorganic growth or future fundraising will be evaluated in consultation with KKR at an appropriate time.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Healthcare Global Enterprises Ltd Q3 FY25 results?
Revenue growth outlook for FY '25 and beyond remains strong, with Q3 FY '25 recording a 19% year-on-year increase. Expectation of strong year-on-year growth in both top line and bottom line for the next financial year (FY26), as stated by Raj Gore.
What is Healthcare Global Enterprises Ltd share price analysis?
Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.
Is Healthcare Global Enterprises Ltd planning capital expenditure?
Current and near-term capex guidance is INR 275–280 crores per annum for FY '25 and FY '26.
Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.